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Introduction {#cam41220-sec-0001}
============

Pancreatic neuroendocrine tumors (pancreatic NETs) are rare pancreatic neoplasms with an annual incidence of 1 per 100,000 individuals. The incidence has been rising in the United States and elsewhere over the last two decades, which is due to recent improvements in detecting pancreatic NETs [1](#cam41220-bib-0001){ref-type="ref"}, [2](#cam41220-bib-0002){ref-type="ref"}, [3](#cam41220-bib-0003){ref-type="ref"}. The tumors are categorized as functional or nonfunctional, and approximately 10--30% of pancreatic NETs are functional [4](#cam41220-bib-0004){ref-type="ref"}. They account for 3--5% of pancreatic malignancies and overall have a better prognosis than pancreatic exocrine tumors [5](#cam41220-bib-0005){ref-type="ref"}. The overall 5‐year relative survival rate of pancreatic NETs is approximately 42% [5](#cam41220-bib-0005){ref-type="ref"}. There are some prognostic factors of pancreatic NETs being reported in studies, including tumor‐size, histologic grade, TNM stage, treatment strategy, and marital status [6](#cam41220-bib-0006){ref-type="ref"}, [7](#cam41220-bib-0007){ref-type="ref"}. Studies about the impact of race and ethnicity on tumors have published widely in recent years [8](#cam41220-bib-0008){ref-type="ref"}, [9](#cam41220-bib-0009){ref-type="ref"}, [10](#cam41220-bib-0010){ref-type="ref"}. Black patients or African American patients are associated with the poor overall survival in a variety of tumors. However, no study has rigorously explored the impact of ethnic disparity on survival of patients with pancreatic NETs. Our study aimed to demonstrate the relationship between ethnic disparity and survival in pancreatic NETs patients using the Surveillance, Epidemiology, and End Results (SEER) database.

Materials and Methods {#cam41220-sec-0002}
=====================

Patients selection {#cam41220-sec-0003}
------------------

The SEER\*Stat software version 8.3.2 (accession number: 13693‐Nov2015) was used to extract data from the SEER database [11](#cam41220-bib-0011){ref-type="ref"}, [12](#cam41220-bib-0012){ref-type="ref"}. We identified patients diagnosed with pancreatic NETs that were reported to the SEER database from 2004 to 2013. ICD‐O‐3 (International Classification of Diseases for Oncology, 3rd edition) morphology codes 8150, 8151, 8152, 8153, 8155, 8156, 8157, 8240, 8241, 8242, 8243, 8246, and 8249 were used to identify pancreatic NETs. All pancreatic anatomical sites (C25.0---C25.9) were included in the study [13](#cam41220-bib-0013){ref-type="ref"}.

The exclusion criteria were as follows: (1) who had more than one primary cancer and the pancreatic NETs was not the first; (2) incomplete follow‐up information or unknown survival length; (3) and who had an unknown cause of death; (4) and who had incomplete county‐level socioeconomic data [14](#cam41220-bib-0014){ref-type="ref"}.

Variable definition {#cam41220-sec-0004}
-------------------

We included variabilities as sex, age, marital status, education, income, tumor location, tumor size, metastatic status, histologic type, pathology grade, extent of disease, TNM stage, surgery, and race. We grouped races as "Black" and "White/Other" (non‐Black). Marital status was divided as married, unmarried, and unknown. We included socioeconomic status (SES, an economic, and sociological combined total measure) related variables as following: education (the percentage of adults aged ≥25 years who \<12 years of education), poverty (the percentage of individuals living below the poverty line), and income (median annual household income). These variables were used as continuous variables in this study. According to the definitions of Country Attributes in SEER data, the higher values of the variables of education and poverty are, the lower the values of SES are. SEER staging was used to define disease extension: localized, regional and distant [15](#cam41220-bib-0015){ref-type="ref"}. CS Mets at Dx(metastatic status) identifies whether there is metastatic involvement of distant site(s) at the time of diagnosis. CS Mets at Dx is part of the Collaborative Stage Data Collection System (CS), and was first introduced in 2004. It is used to derive some American Joint Committee on Cancer TNM Staging System (AJCC) M values and SEER Summary Stage codes [16](#cam41220-bib-0016){ref-type="ref"}. The CS Mets at Dx was introduced into yes, no and unknown. We set 2 and 4 cm as the cutoff points of tumor size according to The European Neuroendocrine Tumor Society Staging Classification (ENETS) [17](#cam41220-bib-0017){ref-type="ref"}.

Outcomes {#cam41220-sec-0005}
--------

The primary outcomes of this study were overall survival and pancreatic neuroendocrine tumors specific survival. OS was defined as the time from diagnosis to date of any death. pancreatic neuroendocrine tumors specific survival (PNSS) was derived from the time of diagnosis to date of pancreatic NETs cancer‐specific death. Death attributed to pancreatic NETs was regarded as an event. Patients who died from other causes or were still alive at the follow‐up cutoff date were treated as censored observations [14](#cam41220-bib-0014){ref-type="ref"}. The follow‐up cutoff date was December 31, 2013.

Statistical analyses {#cam41220-sec-0006}
--------------------

The baseline patients' demographic characteristics, tumor characteristics, and treatments were compared by Mann--Whitney *U* test (continuous variables) or Pearson chi‐squared test (categorical variables). Kaplan--Meier curve was used to describe the overall survival, pancreatic neuroendocrine tumors specific survival and the differences between groups were tested by log‐rank method. Factors significantly relating to outcomes in the univariate analysis were selected for the Cox proportional hazard model for recognizing confounding factors. Thus, we wound see whether race impacted the survival time of pancreatic NETs. We also stratified each ethnic group into different SEER stages at diagnosis and different surgical status, so that subgroup analysis was carried out. Statistical significance was set at two‐sided *P *\<* *0.05. All statistical analyses were performed using R 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria; [www.r-project.org](http://www.r-project.org)).

Results {#cam41220-sec-0007}
=======

Population characteristics {#cam41220-sec-0008}
--------------------------

Based on selection criteria, this retrospective cohort study included a total of 3852 patients who were diagnosed with pancreatic NETs from 2004 to 2013. The population characteristics are summarized in Table [1](#cam41220-tbl-0001){ref-type="table-wrap"}. Among them, 3357 (87%) were non‐Black patients, 493 (13%) were Blacks (*P *\<* *0.001). The Black patients had a lower percentage of males, younger average age and a lower marriage rate (*P *\<* *0.001). The socioeconomic status of Blacks was significantly unfavorable than non‐Black patients' condition, including education (*P *=* *0.051), higher poverty rate (*P *\<* *0.001) and lower annual income (*P *\<* *0.001). Blacks were more likely to be diagnosed with later stages of tumors (*P *=* *0.021). As for the treatment, the access to surgery seemed to be more limited in Blacks than non‐Black patients (*P *=* *0.012). We found no statistically significant differences between the ethnicities in other characteristics including tumor size, histology type, pathology grade and AJCC groups (*P *\>* *0.05).

###### 

Baseline demographic and tumor characteristics of patients in Surveillance, Epidemiology, and End Results (SEER) database

  Characteristics                                             Total               White/Other         Black               *P* value
  ----------------------------------------------------------- ------------------- ------------------- ------------------- -----------
  Sex                                                                                                                     \<0.001
  Male                                                        2118 (55.0)         1894 (56.4)         224 (45.4)          
  Female                                                      1732 (45.0)         1463 (43.6)         269 (54.6)          
  Age at diagnosis (mean \[SD\])                              59.36 (13.98)       59.78 (13.96)       56.54 (13.82)       \<0.001
  Marital status                                                                                                          \<0.001
  Married                                                     2402 (62.4)         2201 (65.6)         201 (40.8)          
  Unknown                                                     181 (4.7)           153 (4.6)           28 (5.7)            
  Unmarried                                                   1267 (32.9)         1003 (29.9)         264 (53.5)          
  Education (mean \[SD\])                                     14.98 (6.16)        14.91 (6.29)        15.49 (5.18)        0.051
  Poverty (mean \[SD\])                                       14.23 (5.13)        13.90 (5.03)        16.50 (5.24)        \<0.001
  Income (mean (SD))[a](#cam41220-note-0003){ref-type="fn"}   6078.42 (1479.09)   6161.98 (1489.22)   5509.43 (1270.79)   \<0.001
  Primary Site                                                                                                            \<0.001
  Body                                                        478 (12.4)          412 (12.3)          66 (13.4)           
  Head                                                        1180 (30.6)         1012 (30.1)         168 (34.1)          
  Others                                                      1046 (27.2)         894 (26.6)          152 (30.8)          
  Tail                                                        1146 (29.8)         1039 (31.0)         107 (21.7)          
  Metastatic status                                                                                                       0.322
  No                                                          1975 (51.3)         1733 (51.6)         242 (49.1)          
  Unknown                                                     101 (2.6)           91 (2.7)            10 (2.0)            
  Yes                                                         1774 (46.1)         1533 (45.7)         241 (48.9)          
  Tumor size                                                                                                              0.111
  \<2 cm                                                      674 (17.5)          599 (17.8)          75 (15.2)           
  \>4 cm                                                      1359 (35.3)         1175 (35.0)         184 (37.3)          
  2--4 cm                                                     1210 (31.4)         1067 (31.8)         143 (29.0)          
  Unknown                                                     607 (15.8)          516 (15.4)          91 (18.5)           
  Histology                                                                                                               0.108
  Functional                                                  100 (2.6)           93 (2.8)            7 (1.4)             
  Nonfunctional                                               3750 (97.4)         3264 (97.2)         486 (98.6)          
  Grade                                                                                                                   0.179
  Grade I                                                     1435 (37.3)         1265 (37.7)         170 (34.5)          
  Grade II                                                    371 (9.6)           325 (9.7)           46 (9.3)            
  Grade III                                                   258 (6.7)           219 (6.5)           39 (7.9)            
  Grade IV                                                    67 (1.7)            63 (1.9)            4 (0.8)             
  Unknown                                                     1719 (44.6)         1485 (44.2)         234 (47.5)          
  Disease extension (%)                                                                                                   0.021
  Distant                                                     1875 (48.7)         1623 (48.3)         252 (51.1)          
  Localized                                                   1102 (28.6)         988 (29.4)          114 (23.1)          
  Regional                                                    780 (20.3)          669 (19.9)          111 (22.5)          
  Unknown                                                     93 (2.4)            77 (2.3)            16 (3.2)            
  AJCC groups (%)                                                                                                         0.232
  I/II                                                        1144 (29.7)         1009 (30.1)         135 (27.4)          
  III/IV                                                      1562 (40.6)         1345 (40.1)         217 (44.0)          
  Unknown                                                     1144 (29.7)         1003 (29.9)         141 (28.6)          
  Surgery (%)                                                                                                             0.012
  Yes                                                         1887 (49.0)         1676 (49.9)         211 (42.8)          
  No                                                          1951 (50.7)         1671 (49.8)         280 (56.8)          
  Unknown                                                     12 (0.3)            10 (0.3)            2 (0.4)             

Income is displayed as dollars in tens in SEER database (e.g., 6688 represents \$66,880).
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Ethnic disparity in OS in overall pancreatic NETs population {#cam41220-sec-0009}
------------------------------------------------------------

As the OS Kaplan--Meier curve shown in Figure [1](#cam41220-fig-0001){ref-type="fig"}A, there was a significant survival difference according to race (log rank test *P *=* *0.008). Compared with other racial groups, Black patients have worse OS. The 5‐year OS was 45.0% in Black patients, 50.3% in other racial groups. Similarly, the median OS of Black patients (43 months) was lower than the others (61 months). According to univariate log‐rank test, several variables were closely associated with OS, including sex, age, marital status, education, poverty, income, primary site, tumor size, metastatic status, histologic type, pathology grade, extension of disease, AJCC stage, and surgical status. Race was still an independent prognostic factor after adjusting for aforementioned variables in the Cox proportional hazard regression model, and Black patients have worse OS than non‐Black patients (hazard ratio \[HR\] = 1.17, confidence interval \[95% CI\]: 1.00--1.37, *P *=* *0.046) (Table [2](#cam41220-tbl-0002){ref-type="table-wrap"}).

![Survival curves in patients with pancreatic neuroendocrine tumors between Black and White/Other. (A) Overall survival (OS): *χ* ^2^ = 7.21, *P *=* *0.008. (B) Pancreatic neuroendocrine tumors cause specific survival (PNSS): *χ* ^2^ = 6.11, *P *=* *0.014.](CAM4-6-2745-g001){#cam41220-fig-0001}

###### 

Univariate and Multivariate survival analysis of OS in pancreatic endocrine tumor patients. Surveillance, Epidemiology, and End Results 2004--2013 (*n* = 3850)

  Characteristic      Univariate analysis   Multivariate analysis                            
  ------------------- --------------------- ----------------------- ----------- ------------ ---------
  Sex                 8.77                  0.003                                            
  Female                                                            Reference                
  Male                                                              1.16        1.04--1.29   0.008
  Age at diagnosis    230.42                \<0.001                 1.03        1.02--1.03   \<0.001
  Marital status      38.52                 \<0.001                                          
  Married                                                           Reference                
  Unknown                                                           0.92        0.70--1.21   0.540
  Unmarried                                                         1.28        1.15--1.44   \<0.001
  Education           1.00                  0.318                   1.00        0.99--1.01   0.659
  Poverty             5.87                  0.015                   1.01        0.99--1.03   0.502
  Income              8.05                  0.005                   1.00        0.99--1.00   0.817
  Primary site        58.06                 \<0.001                                          
  Body                                                              Reference                
  Head                                                              1.02        0.85--1.23   0.806
  Tail                                                              0.95        0.79--1.15   0.627
  Others                                                            1.07        0.89--1.29   0.485
  Metastatic status   825.83                \<0.001                                          
  No                                                                Reference                
  Unknown                                                           1.50        1.03--2.19   0.035
  Yes                                                               1.19        0.88--1.60   0.258
  Tumor size          356.80                \<0.001                                          
  \<2 cm                                                            Reference                
  \>4 cm                                                            1.25        0.98--1.60   0.074
  2--4 cm                                                           1.33        1.04--1.69   0.025
  Unknown                                                           1.42        1.10--1.84   0.007
  Histology           14.06                 \<0.001                                          
  Functional                                                        Reference                
  Nonfunctional                                                     1.18        0.79--1.78   0.415
  Grade               681.25                \<0.001                                          
  Grade II                                                          Reference                
  Grade I                                                           0.85        0.67--1.08   0.174
  Grade III                                                         3.07        2.39--3.94   0.000
  Grade IV                                                          3.68        2.60--5.23   0.000
  Unknown                                                           1.41        1.14--1.75   0.001
  Disease extension   828.12                \<0.001                                          
  Distant                                                           Reference                
  Localized                                                         0.41        0.29--0.6    \<0.001
  Regional                                                          0.83        0.60--1.16   0.277
  Unknown                                                           0.55        0.34--0.89   0.016
  AJCC groups         783.26                \<0.001                                          
  I/II                                                              Reference                
  III/IV                                                            1.55        1.20--2.00   0.001
  Unknown                                                           1.10        0.87--1.39   0.430
  Surgery             1041.55               \<0.001                                          
  No                                                                Reference                
  Yes                                                               0.38        0.32--0.45   \<0.001
  Unknown                                                           1.53        0.75--3.09   0.241
  Race                7.21                  0.008                                            
  White/Other                                                       Reference                
  Black                                                             1.17        1.00--1.37   0.046
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Ethnic disparity in PNSS in overall pancreatic NETs population {#cam41220-sec-0010}
--------------------------------------------------------------

As the PNSS Kaplan--Meier curve shown in Figure [1](#cam41220-fig-0001){ref-type="fig"}B, Blacks have worse PNSS compared to non‐Black patients (*P *=* *0.014). The 5‐year PNSS of Blacks is 59.4%, and 65.2% in other racial groups. The median PNSS of Black patients (96 months) is still lower than non‐Black patients (over 103 months). Univariate log‐rank test shows that several variables are closely associated with PNSS, including sex, age, marital status, education, poverty, income, primary site, tumor size, metastatic status, histologic type, pathology grade, extent of disease, AJCC stage, and surgical status. The multivariate Cox regression analysis show that race is still an independent prognostic factor, and Black patients have worse PNSS than non‐Black patients (HR = 1.22, 95% CI: 1.01--1.48, *P *=* *0.044) (Table [3](#cam41220-tbl-0003){ref-type="table-wrap"}).

###### 

Univariate and Multivariate survival analysis of PNSS in pancreatic endocrine tumor patients. Surveillance, Epidemiology, and End Results 2004--2013 (*n* = 3850)

  Characteristic      Univariate analysis   Multivariate analysis                            
  ------------------- --------------------- ----------------------- ----------- ------------ ---------
  Sex                 9.86                  0.002                                            
  Female                                                            Reference                
  Male                                                              1.18        1.03--1.35   0.020
  Age at diagnosis    144.28                \<0.001                 1.03        1.02--1.03   \<0.001
  Marital status      16.50                 \<0.001                                          
  Married                                                           Reference                
  Unknown                                                           0.88        0.62--1.26   0.490
  Unmarried                                                         1.20        1.04--1.38   0.014
  Education           1.74                  0.187                   1.01        0.99--1.02   0.291
  Poverty             4.07                  0.044                   1.00        0.97--1.02   0.744
  Income              6.78                  0.009                   1.00        0.99--1.00   0.360
  Primary site        43.48                 \<0.001                                          
  Body                                                              Reference                
  Head                                                              1.22        0.97--1.55   0.093
  Tail                                                              1.00        0.78--1.29   0.974
  Others                                                            1.12        0.87--1.43   0.379
  Metastatic status   563.69                \<0.001                                          
  No                                                                Reference                
  Unknown                                                           1.81        1.13--2.90   0.014
  Yes                                                               1.12        0.79--1.60   0.529
  Tumor size          179.55                \<0.001                                          
  \<2 cm                                                            Reference                
  \>4 cm                                                            1.14        0.83--1.56   0.407
  2--4 cm                                                           1.21        0.88--1.66   0.239
  Unknown                                                           1.11        0.80--1.54   0.545
  Histology           16.04                 \<0.001                                          
  Functional                                                        Reference                
  Nonfunctional                                                     1.73        0.91--3.29   0.096
  Grade               553.52                \<0.001                                          
  Grade II                                                          Reference                
  Grade I                                                           0.77        0.56--1.05   0.101
  Grade III                                                         3.47        2.55--4.73   \<0.001
  Grade IV                                                          3.97        2.61--6.06   \<0.001
  Unknown                                                           1.45        1.10--1.90   0.007
  Disease extension   587.99                \<0.001                                          
  Distant                                                           Reference                
  Localized                                                         0.24        0.15--0.39   \<0.001
  Regional                                                          0.82        0.55--1.22   0.336
  Unknown                                                           0.41        0.22--0.75   0.004
  AJCC groups         558.94                \<0.001                                          
  I/II                                                              Reference                
  III/IV                                                            1.64        1.17--2.29   0.004
  Unknown                                                           1.16        0.86--1.59   0.333
  Surgery             682.66                \<0.001                                          
  No                                                                Reference                
  Yes                                                               0.37        0.30--0.45   \<0.001
  Unknown                                                           1.16        0.43--3.13   0.772
  Race                6.11                  0.014                                            
  White/Other                                                       Reference                
  Black                                                             1.22        1.01--1.48   0.044
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Ethnic disparity in OS and PNSS in patients stratified by SEER stage {#cam41220-sec-0011}
--------------------------------------------------------------------

We also explored the survival patterns among ethnicities in subgroups stratified by SEER stage at diagnosis: localized (28.6%), regional (20.2%), and distant (48.7%) (*P *=* *0.003). We excluded the unstaged patients and patients whose stages at diagnosis were unknown, which only added up to 2.4% of the total. The patients whose stages at diagnosis were localized accounted for 28.6% of the total patients: 23.1% of Blacks (*n* = 114), 29.4% of non‐Blacks (*n* = 988). The patients whose stages at diagnosis were regional accounted for 20.2% of the total patients: 22.5% of Blacks (*n* = 111), 19.9% of non‐Blacks (*n* = 669). The patients whose stages at diagnosis were distant accounted for 48.7% of the total patients: 51.1% of Blacks (*n* = 252), 48.3% of non‐Blacks (*n* = 1623).

As is shown in Figure [2](#cam41220-fig-0002){ref-type="fig"}C, for the patients whose stages at diagnosis were localized, of interest, Blacks (HR = 2.09, 95% CI: 1.18--3.71, *P *=* *0.011) had an extremely worse OS compared to non‐Black patients. And the PNSS for Blacks (HR = 3.79, 95% CI: 1.62--8.82, *P *=* *0.002), shown in Figure [2](#cam41220-fig-0002){ref-type="fig"}D, was extraordinarily worse compared to non‐Black patients. As for the patients whose stages at diagnosis were regional and distant, the survival disparity of Blacks and non‐Blacks was not significant (Fig. [2](#cam41220-fig-0002){ref-type="fig"} A, B, E and F, Table [4](#cam41220-tbl-0004){ref-type="table-wrap"}).

![Survival curves in different Surveillance, Epidemiology, and End Results (SEER) stage subgroup patients with pancreatic neuroendocrine tumors according to race. (A). Distant, Overall survival (OS): *χ* ^2^ = 4.32, *P *=* *0.037; (B). Distant, Pancreatic neuroendocrine tumors cause specific survival (PNSS): *χ* ^2^ = 3.19, *P *=* *0.073; (C). Localized, OS:*χ* ^2^ = 3.31, *P *=* *0.068; (D). Localized, PNSS:*χ* ^2^ = 8.76, *P *=* *0.003; (E). Regional, OS:*χ* ^2^ = 0.19, *P* = 0.666; (F). Regional, PNSS:*χ* ^2^ = 0.53, *P *=* *0.465.](CAM4-6-2745-g002){#cam41220-fig-0002}

###### 

Univariate and Multivariate survival analysis of pancreatic endocrine tumor survival based on different extension. Surveillance, Epidemiology, and End Results 2004--2013 (*n* = 3850)

  Characteristic                 Univariate analysis   Multivariate analysis                            
  ------------------------------ --------------------- ----------------------- ----------- ------------ -------
  Overall survival                                                                                      
  *Localized*                    3.31                  0.068                                            
  White/Other                                                                  Reference                
  Black                                                                        2.09        1.18--3.71   0.011
  *Distant*                      4.32                  0.037                                            
  White/Other                                                                  Reference                
  Black                                                                        1.17        0.98--1.39   0.086
  *Regional*                     0.19                  0.666                                            
  White/Other                                                                  Reference                
  Black                                                                        1.06        0.68--1.66   0.797
  PNET cause‐specific survival                                                                          
  *Localized*                    8.76                  0.003                                            
  White/Other                                                                  Reference                
  Black                                                                        3.79        1.62--8.82   0.002
  *Distant*                      3.19                  0.073                                            
  White/Other                                                                  Reference                
  Black                                                                        1.22        0.98--1.52   0.072
  *Regional*                     0.53                  0.465                                            
  White/Other                                                                  Reference                
  Black                                                                        1.16        0.68--1.98   0.584

PNET, pancreatic neuroendocrine tumor (pancreatic NETs).
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Ethnic disparity in OS and PNSS in patients stratified by surgical status {#cam41220-sec-0012}
-------------------------------------------------------------------------

We also explored the survival patterns among ethnicities in subgroups stratified by surgical status: surgery performed (50.7%), and no surgery performed (49.0%) (*P *=* *0.012). We excluded the patients with unknown surgical status (0.3%). The patients who received surgery accounted for 50.7% of the total, 42.8% of Blacks (*n* = 211), and 49.9% of non‐Blacks (*n* = 1676). The patients who did not receive surgery accounted for 49.0% of the total, 56.8% of Blacks (*n* = 280), and 49.8% of non‐Blacks (*n* = 1671). As for the patients who did not receive surgery, Blacks (HR = 1.18, 95% CI: 1.00--1.41, *P *=* *0.045) have a significantly worse OS than non‐Black patients (Fig. [3](#cam41220-fig-0003){ref-type="fig"}C). The PNSS for Blacks (HR = 1.21, 95% CI: 0.98--1.50, *P *=* *0.071), however, has no significant disparity (Fig. [3](#cam41220-fig-0003){ref-type="fig"}D). For the patients who received surgery, both the OS (HR = 1.07, 95% CI: 0.71--1.61, *P *=* *0.74) and PNSS (HR = 1.20, 95% CI: 0.71--2.02, *P *=* *0.50) for Blacks display no significant disparity (Fig. [3](#cam41220-fig-0003){ref-type="fig"}A, B, Table [5](#cam41220-tbl-0005){ref-type="table-wrap"}).

![Survival curves in different surgical status subgroup patients with pancreatic neuroendocrine tumors according to race. (A). Received Surgery, Overall survival (OS): *χ* ^2^ = 0.01, *P *=* *0.937; (B). Received Surgery, Pancreatic neuroendocrine tumors cause specific survival (PNSS): *χ* ^2^ = 0.04, *P *=* *0.850; (C). Not Received Surgery, OS:*χ* ^2^ = 1.94, *P *=* *0.164; (D). Not Received Surgery, PNSS:*χ* ^2^ = 1.56, *P *=* *0.212.](CAM4-6-2745-g003){#cam41220-fig-0003}

###### 

Univariate and Multivariate survival analysis of pancreatic endocrine tumor survival based on surgical status. Surveillance, Epidemiology, and End Results 2004--2013 (*n* = 3850)

  Characteristic                 Univariate analysis   Multivariate analysis                            
  ------------------------------ --------------------- ----------------------- ----------- ------------ -------
  Overall survival                                                                                      
  *Received surgery*             0.01                  0.937                                            
  White/Other                                                                  Reference                
  Black                                                                        1.07        0.71--1.61   0.744
  *Not received surgery*         1.94                  0.164                                            
  White/Other                                                                  Reference                
  Black                                                                        1.19        1.00--1.41   0.045
  PNET cause‐specific survival                                                                          
  *Received surgery*             0.04                  0.850                                            
  White/Other                                                                  Reference                
  Black                                                                        1.20        0.71--2.02   0.496
  *Not received surgery*         1.56                  0.212                                            
  White/Other                                                                  Reference                
  Black                                                                        1.21        0.98--1.50   0.071

PNET, pancreatic neuroendocrine tumor (pancreatic NETs).
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Discussion {#cam41220-sec-0013}
==========

Our study shows the racial disparities among pancreatic NETs patients. As shown in the univariable and multivariable analysis, the Black patients have worse OS and PNSS than other racial groups, even after adjusting for sex, age, marital status, presence of distant metastasis, tumor size, histology, grade, AJCC stage, disease extension, and therapies. Actually, Yao and Dasari have reported the same worse overall survival for African American patients with pancreatic NETs, but without in‐depth exploration about factors influencing outcome [18](#cam41220-bib-0018){ref-type="ref"}, [19](#cam41220-bib-0019){ref-type="ref"}. We want to explore the reasons behind the phenomenon to have a better understanding of its contributors, which will provide useful inventions to reduce the disparity. Several factors have previously been studied in articles about ethnic disparity in survival for other tumors, such as marital status, SES, advanced stage and treatment [8](#cam41220-bib-0008){ref-type="ref"}, [9](#cam41220-bib-0009){ref-type="ref"}, [10](#cam41220-bib-0010){ref-type="ref"}.

According to the demographics of SEER patients, Blacks had a more advanced tumor stage at the moment of diagnosis comparing to non‐Black patients. Several studies supported the reason for delayed diagnosis may be due to Blacks' low marriage rate and unfavorable SES [20](#cam41220-bib-0020){ref-type="ref"}, [21](#cam41220-bib-0021){ref-type="ref"}, [22](#cam41220-bib-0022){ref-type="ref"}. Previous studies demonstrated that marriage is associated with earlier stage at diagnosis and more favorable survival for various cancer type [22](#cam41220-bib-0022){ref-type="ref"}, [23](#cam41220-bib-0023){ref-type="ref"}, [24](#cam41220-bib-0024){ref-type="ref"}, [25](#cam41220-bib-0025){ref-type="ref"}, [26](#cam41220-bib-0026){ref-type="ref"}. It is also the case in pancreatic NETs. Our previous study revealed that being married contributes to a better survival in pancreatic NETs patients [14](#cam41220-bib-0014){ref-type="ref"}. Also, SES could be the potential contributor to ethnical survival disparity as it can affect the usage of medical resources of pancreatic NETs patients. Julien et al. found that SES are associated with treatment choice in pancreatic NETs [27](#cam41220-bib-0027){ref-type="ref"}. Blacks are more likely to be in disadvantaged SES, and tend to cluster in low quality hospital [28](#cam41220-bib-0028){ref-type="ref"}, [29](#cam41220-bib-0029){ref-type="ref"}.

Of interest, our subgroup analysis demonstrates that Blacks whose stage at diagnosis were localized had significantly worse OS and PNSS compared with non‐Black patients. However, we found no special disparity in distant and regional patients, that means race was an independent prognostic factor for OS and PNSS in localized disease, but not in regional disease or distant stage disease. We speculated that the reason may be that effective health care was not available to Blacks in the early stage.

Our analysis showed that access to effective options of treatment may be a reason for the poor survival of Blacks. The only curative treatment of pancreatic NETs is radical surgery. The majority of studies have demonstrated that Black patients with pancreatic cancer are less likely to undergo resection and have worse outcomes compared with white patients [8](#cam41220-bib-0008){ref-type="ref"}, [13](#cam41220-bib-0013){ref-type="ref"}, [16](#cam41220-bib-0016){ref-type="ref"}. Our study agreed with the above: Blacks had less surgical treatment compared to Whites and Others (42.8% vs. 49.9%, *P *=* *0.012). As for those patients underwent surgery, the OS and PNSS display no significant racial disparity. However, contrary to our study, a pancreatic NETs research based on National Cancer Database reported that race was not associated with treatment choice or survival in pancreatic NETs [27](#cam41220-bib-0027){ref-type="ref"}. The possible reason may be different select criteria, and what they focused on were patients with non‐metastatic. Our results suggested that surgery may be underused for Blacks due to unfavorable SES. And maximizing surgery rates appropriately may be good for reducing racial disparities for pancreatic NETs.

Though those factors above may partly contribute to the poor survival of Blacks, in our multivariate analysis, we could still observe the influence on pancreatic NETs' survival by race itself. We made a hypothesis that genetic differences between races and ethnicities may be a significant reason to pancreatic NETs survival disparity. Previous studies on racial disparities in cancer attribute some of the difference in survival to tumor biology and genetic variation, especially in prostate cancer and breast cancer [30](#cam41220-bib-0030){ref-type="ref"}, [31](#cam41220-bib-0031){ref-type="ref"}, [32](#cam41220-bib-0032){ref-type="ref"}. For instance, a study showed that miR‐24 expression was linked to a racial difference between African‐American and Caucasian--American, which could contribute to race‐related tumorigenesis in prostate cancer [30](#cam41220-bib-0030){ref-type="ref"}. Also, for multiple myeloma, African American\'s higher levels of phenotypic heterogeneity and monoclonal immunoglobulin levels caused the unfavorable survival, compared with their white counterparts [33](#cam41220-bib-0033){ref-type="ref"}. Compared with Whites, African Americans have also been proved to have worse survival in other tumors due to racial genetic differences, including head and neck squamous cell carcinoma, kidney cancer [34](#cam41220-bib-0034){ref-type="ref"}, [35](#cam41220-bib-0035){ref-type="ref"}. However, no study has specifically explored pancreatic NETs‐related genetic differences in races and ethnicities and their contribution to pancreatic NETs survival disparity. Based on these findings above, we speculated that genetic differences may contribute to race disparity in pancreatic NETs survival. Further studies are required.

Our study also had limitations. First, as pancreatic NETs is a rare disease, the sample size is relatively small. Second, the SEER database does not provide patient‐level socioeconomic information, and the county‐level information can not reflect the socioeconomic condition of individual patients, which may have a significant impact on patients' access to medical care and their survival. Third, the clinical details are not available from SEER database, which may affect the use of therapies and the survival. Fourth, the recurrence information is unavailable, so the differences in recurrence rates could not be examined. Finally, for lack of evidence, we were unable to know how ethnic disparity effected on survival due to our research design. Further studies are required to gain more evidence to confirm the findings.

Conclusion {#cam41220-sec-0014}
==========

In conclusion, our study has found that Blacks had unfavorable OS and PNSS compared with non‐Black patients. Poor prognosis of Black patients may be associated with advanced disease extension at diagnosis, limited utilization of surgery. Also, we speculated that the ethnicity‐related genetic differences may contribute to the survival disparity of pancreatic NETs patients. Further studies are required on our findings.
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